OMRIX TO BEGIN TRIAL OF INTRAVENOUS IMMUNOGLOBULIN

Omrix Biopharmaceuticals announced it will begin a Phase III open-label, single-arm, multicenter clinical trial for treatment of primary immune deficiency with Omr-IgG-am, the company's intravenous immunoglobulin (IVIG) currently marketed outside of the U.S.

IVIG contains the spectrum of antibodies normally present in healthy adult human plasma. It can be used to provide ongoing treatment for primary and secondary immune deficiencies as well as replacement therapy by providing a broad selection of antibodies that mimic a healthy immune system.

Omr-IgG-am is a highly purified IVIG solution containing more than 95 percent IgG and only small traces of IgA. The physiological distribution of the IgG subclass is maintained due to a highly effective production process. Two virus removal and/or inactivation steps ensure safety without altering efficiency. Omr-IgG -am does not contain sucrose or albumin.